Genetically Engineered Electrically-Stimulated Effector Cells for In Situ Protein Synthesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current standard-of-care therapeutics for immunological diseases, such as viral diseases and cancers, are resource-intensive and time-consuming to develop, and vaccine development is challenged by emerging variants that can evade immunity, leading to new waves of illness.
Innovation Solution
Genetically engineered electrically-stimulated effector cells that include an exogenous polynucleotide sequence with a voltage-gated calcium ion channel, transcription factor binding site, and effector protein, allowing for in situ synthesis and secretion of therapeutic proteins in response to electrical stimulation, potentially addressing the need for rapid and targeted treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard-of-care therapeutics and vaccines are developed for each viral pathogen, then treatment effectiveness is improved, but development time and resource consumption increase significantly
Solution Approach 1:
The patent creates a universal cell-based platform that can produce multiple different therapeutic proteins (viral antigens, antibodies, cytokines) through electrical stimulation. The genetically engineered cells contain modular polynucleotide sequences that can be reconfigured to express different effector proteins, allowing a single cell line to serve multiple therapeutic purposes across different viral pathogens without requiring separate vaccine development for each pathogen.
Solution Approach 2:
The cells are pre-engineered with the complete machinery (voltage-gated calcium channels, transcription factor binding sites, effector protein genes) ready for immediate activation. When a viral threat emerges, the pre-prepared cells can be rapidly stimulated electrically to produce the needed therapeutic proteins within hours, bypassing the traditional lengthy vaccine development process while maintaining treatment effectiveness.
2Reliability
If traditional vaccine development processes are used for each emerging pathogen, then pathogen-specific immunity is achieved, but resource intensity and cost increase
Solution Approach 1:
A single population of genetically engineered cells serves as a universal platform for producing multiple pathogen-specific therapeutics. The cells contain interchangeable polynucleotide sequences that can be adjusted to produce antigens or antibodies against different viruses, eliminating the need to develop and maintain separate cell lines or manufacturing processes for each pathogen, thereby reducing overall resource consumption.
Solution Approach 2:
The cells autonomously produce the required therapeutic proteins when electrically stimulated, utilizing their own cellular machinery (transcription, translation, secretion systems). This self-service capability eliminates the need for external protein purification and manufacturing facilities, significantly reducing the resources required compared to traditional vaccine production methods.
3Reliability
If therapeutics are administered systemically to treat disease, then treatment coverage is improved, but toxicity to healthy tissues increases
Solution Approach 1:
The therapeutic effect is localized to the site where genetically engineered cells are administered. When these cells migrate to or are delivered at the infection site and are electrically stimulated, they produce therapeutic proteins locally at the target location. This localized production ensures comprehensive treatment coverage at the infection site while minimizing exposure and toxicity to distant healthy tissues throughout the body.
Solution Approach 2:
The genetically engineered cells act as living intermediaries that deliver therapeutic proteins directly to the target site. Rather than administering therapeutics systemically that then distribute throughout the body, the cells serve as localized factories that produce and secrete therapeutic proteins exactly where needed, mediated by electrical stimulation at the target location, thereby reducing systemic toxicity while maintaining effective treatment coverage.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These cells can provide a rapid and calibrated production of therapeutic proteins, including antiviral agents, at the site of infection, potentially offering a solution for emerging pathogens and reducing the need for specific vaccine development for each viral pathogen, enhancing treatment efficacy and reducing systemic toxicity.
Implementation Method 1
an electrical-sensor element that encodes a voltage-gated calcium ion channel (CaV), wherein the CaV is configured to transition from a closed state to an open state in response to electrical stimulation
Implementation Method 2
in response to electrical stimulation
Implementation Method 3
the influx of Ca+2 activates the transcription factor binding site and causes the upregulation of the synthesis of the effector protein
Data Source
AI summary
An example genetically engineered electrically-stimulated (ES) cell comprises an exogenous polynucleotide sequence that includes an electrical-sensor element, an actuator element, and an effector element. The electrical-sensor element encodes a voltage-gated calcium ion channel (CaV), wherein the CaV is configured to transition from a closed state to an open state in response to stimulation. The actuator element encodes a transcription factor binding site that upregulates synthesis of an effector protein. The effector element encodes the effector protein, wherein, in response to the transition of the CaV to the open state, the genetically engineered ES effector cell is configured to activate and, to synthesize and secrete the effector protein.